

**INDEPENDENT PATIENT REVIEW PANEL (IPRP)**  
**Individual Funding Request (IFR)**  
**TERMS OF REFERENCE**

**1. Purpose**

The Individual Funding Request Panel will consider requests on an individual named basis for treatments either not covered by commissioning arrangements or where a treatment is specifically excluded from those arrangements.

The panel will be responsible for assessing the clinical effectiveness of the procedure and then the cost effectiveness of the requested treatment based on the evidence available to them at the time. For requests where a treatment is excluded from commissioning arrangements the panel will review the evidence to determine whether or not the request under consideration is exceptional and should therefore have access to that treatment funded by the NHS.

The panel will convene monthly to review requests for funding for treatments not currently covered by commissioning arrangements or for treatments excluded from those arrangements. The meeting may be held virtually, either by teleconference or by submission of recommendations from panel members, or the meeting will be a face to face.

The panel will adopt a consensus approach to decision making where unanimous view cannot be reached on an individual request. A member of the panel will ensure that the consensus decision is clearly communicated to the EUR team should the meeting be held virtually.

**2. Membership**

- The Lay member for Public and Patient Involvement of the Governing Body (Chair)
- Clinician – either Chief Clinical Officer or Deputy Chief Clinical Officer.
- Strategic Director for Corporate Affairs and Resources
- CHC IFR Lead - co-opted as required
- Medicines Management Representative – co-opted as required

Deputies in similar capacity e.g. a GP or Lay or Management Executive representative can be nominated if required.

**3. Administrative Support**

## **Clinical Commissioning Group**

Meetings will be arranged and resourced by the CCG and managed by their nominated lead officer.

Preparation of agendas and all request papers, recording the outcomes of the meeting, taking any actions arising and ensuring letters are sent to the requesting clinician and patient within agreed timescales is the responsibility of the GMCSU EUR team on behalf of the CCG.

Ensuring a suitable venue is available is the responsibility of the CCG lead for IFR.

### **4. Quoracy**

The quorum required for decision-making of the panel will be two panel members to include either the Chief Clinical Officer or the Deputy Chief Clinical Officer and either the Lay member or the Management Executive Team Representative.

If a meeting is not quorate, those members not present will be asked for their decision so that a consensus can be agreed. Where the decision is not unanimous all Panel members will be bound by the majority decision. In the event of a tied vote the Chair of the IFR Panel will have the casting vote.

### **5. Chairs Action / Urgent Decisions**

In clinically urgent situations a request may be considered in advance of the panel using the mechanism agreed in the GM EUR Operational / Policy / Standard Operating Procedures.

### **6. Training of IFR Panel Members**

Training of IFR panel members is the responsibility of the CCG but will be supported by the GMCSU EUR team.

Members should attend at least one meeting per quarter to maintain continuity and expertise.

### **7. Confidentiality**

All requests will be treated as highly confidential as the majority will contain sensitive and/ or clinical information.

Papers will be sent to members via either registered post or a secure e-mail service, e.g. NHS.net.

Consent will be obtained from the patient prior to the meeting.

All confidential papers will be gathered for shredding at the end of the meeting.

### **8. Review**

These terms of reference will be reviewed annually or sooner if there are relevant changes in legislation or local/national guidance.

**IPRP PROCESS REVIEW PANEL  
TERMS OF REFERENCE**

**1. Purpose**

The CCG process review panel will meet on an ad-hoc basis when a patient or clinician acting on their behalf has appealed a panel decision and they have submitted no new evidence in support of their request that needs further consideration by the IFR Panel.

The panel will meet in private but the patient and or a representative will be asked to attend to ensure that their views are fully accounted for.

The panel will adopt a consensus approach to decision making where a unanimous view cannot be reached. If consensus cannot be reached on any point the decision of the chairperson will be final.

The panel will consider each stage of the process that the request has gone through to ensure that all reasonable attempts have been made to find relevant evidence of effectiveness and that all aspects of the request have been considered in the round.

The panel should assure itself that all stages of the process have been recorded.

The panel is there to decide if due process has been followed and to identify any areas where further consideration needs to be made if any.

It is not the role of the CCG process review panel to make a further funding decision or overturn the IFR panel decision; however, it may return the request to the IFR panel to address any issues identified following the process review.

Panels may consider more than one request at a time provided there is sufficient time for each request to be dealt with fully.

**2. Membership**

- Chief Operating Officer
- Governing Body Lay Chair (Chair)
- CCG Chief Clinical Officer or CCG Deputy Chief Clinical Officer (not heard original case)

**Advisory Membership**

- Member of original IFR decision panel
- Member of GMSS EUR staff presenting the case/take the minutes

### **3. Administrative Support**

Meetings will be arranged and resourced by the CCG and managed by their nominated lead officer.

Preparation of agendas and all request papers, recording the outcomes of the meeting, taking any actions arising and ensuring letters are sent to the requesting clinician and patient within agreed timescales is the responsibility of the GMCSU EUR team on behalf of the CCG.

Ensuring a suitable venue is available is the responsibility of the CCG lead for IFR.

### **4. Quoracy**

All members of the panel must be present.

### **5. Training of Process Review Panel Members**

Training of IFR panel members is the responsibility of the CCG but will be supported by the GMCSU EUR team.

CCG process review panel members should ensure that they have received adequate and appropriate training.

### **6. Confidentiality**

All appeals will be treated as highly confidential as the majority will contain sensitive and/or clinical information.

Papers will be sent to members via either registered post or a secure e-mail service (NHS net).

Consent will be obtained from the patient prior to the meeting.

All confidential papers will be gathered for shredding at the end of the meeting.

### **7. Review**

These Terms of Reference will be reviewed annually or sooner if there are relevant changes in legislation or local/national guidance.